GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Gross Margin %

WuXi Biologics (Cayman) (FRA:1FW2) Gross Margin % : 41.93% (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. WuXi Biologics (Cayman)'s Gross Profit for the six months ended in Jun. 2023 was €459 Mil. WuXi Biologics (Cayman)'s Revenue for the six months ended in Jun. 2023 was €1,095 Mil. Therefore, WuXi Biologics (Cayman)'s Gross Margin % for the quarter that ended in Jun. 2023 was 41.93%.


The historical rank and industry rank for WuXi Biologics (Cayman)'s Gross Margin % or its related term are showing as below:

FRA:1FW2' s Gross Margin % Range Over the Past 10 Years
Min: 32.44   Med: 40.8   Max: 46.93
Current: 40.08


During the past 10 years, the highest Gross Margin % of WuXi Biologics (Cayman) was 46.93%. The lowest was 32.44%. And the median was 40.80%.

FRA:1FW2's Gross Margin % is ranked worse than
69.66% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs FRA:1FW2: 40.08

WuXi Biologics (Cayman) had a gross margin of 41.93% for the quarter that ended in Jun. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for WuXi Biologics (Cayman) was 2.70% per year.


WuXi Biologics (Cayman) Gross Margin % Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Gross Margin % Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.64 45.13 46.93 44.04 40.08

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.04 47.36 41.07 41.93 38.25

Competitive Comparison of WuXi Biologics (Cayman)'s Gross Margin %

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Gross Margin % distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Gross Margin % falls into.



WuXi Biologics (Cayman) Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

WuXi Biologics (Cayman)'s Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=910.5 / 2067.446
=(Revenue - Cost of Goods Sold) / Revenue
=(2067.446 - 1156.984) / 2067.446
=44.04 %

WuXi Biologics (Cayman)'s Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=458.9 / 1094.501
=(Revenue - Cost of Goods Sold) / Revenue
=(1094.501 - 635.587) / 1094.501
=41.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


WuXi Biologics (Cayman)  (FRA:1FW2) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

WuXi Biologics (Cayman) had a gross margin of 41.93% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


WuXi Biologics (Cayman) Gross Margin % Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines